8 AI-Powered Patient Recruitment Providers for Clinical Trials in 2026

Roughly 80 percent of clinical trials miss their original enrollment timeline, and a growing group of patient recruitment providers are applying AI and machine learning directly to that problem — reading structured and unstructured electronic health records to surface eligible patients in minutes rather than the weeks a manual chart review takes. This kind of trial recruitment vendor typically works by connecting to a health system or practice's EMR, applying natural language processing or large language models to interpret physician notes and lab values against a study's inclusion and exclusion criteria, then producing a ranked list of candidates for a site to review. The approach differs from traditional advertising-led recruitment in that it starts from existing patient populations rather than trying to attract new ones.

The AI-powered patient recruitment providers below are listed in no particular order and are all currently headquartered in the United States, reflecting where much of this specific technology cluster has concentrated. Between them, these companies and providers cover EMR-based patient matching, natural language processing of unstructured clinical notes, large language model-driven cohort retrieval, and automated outreach and pre-screening.

BEKhealth

BEKhealth's AI-powered platform analyzes both structured and unstructured electronic medical record (EMR) data, using a proprietary ontology built from more than 400 medical libraries mapped against 70,000 trial protocols. The Kent, Washington-based company, founded in 2020, reports its system reads EMR records with roughly 95 percent accuracy and can identify a cohort of tens of thousands of matched patients within seconds. BEKhealth's BEKnetwork connects sponsors to a research-ready network the company describes as spanning more than 30 million patients and 200 research sites. The company has also published benchmark results claiming its clinical language models outperform general-purpose NLP tools from AWS and Google on medical text interpretation tasks.

Cedar Health Research

Cedar Health Research runs its patient-matching technology through a partnership with Aspen Insights, a Fort Worth-based AI and data science firm, integrating directly into the electronic health record and lab systems of partner physician practices across Texas. Founded in 2019 and based in Dallas, the company draws on hundreds of physician practice EMR connections representing well over a million patients to identify trial-eligible candidates from structured and unstructured records. The company has stated a specific focus on recruiting diverse and historically underrepresented patient populations, citing the demographic makeup of the Dallas-Fort Worth market as an advantage. Cedar Health also positions itself as a rescue-site option for sponsors and CROs whose trials are behind on enrollment.

Haystack Health

Haystack Health's flagship platform, Haystack Enroll, applies natural language processing to unstructured medical records to generate precision-matched patient lists for trial eligibility, with AI-assisted chart review built in for validation. The company, founded in 2022, entered a 2023 strategic partnership with Syneos Health to combine capabilities for identifying and enrolling patients, with an initial focus on oncology and immunology trials at Syneos Health sites. Haystack is a portfolio company of Roivant Health. The company reports that more than 90 percent of the inclusion and exclusion insights needed for trial matching are found only in unstructured sections of medical records, which its NLP is built to read.

Infiuss Health

Infiuss Health was founded in 2021 by Melissa Bime, a registered nurse who has said she drew on firsthand experience with healthcare access challenges across Africa in building the company. Based in Buffalo, New York, Infiuss runs an AI-powered platform called Probe that combines project management with tools for participant discovery, protocol automation, and compliance tracking to support decentralized and hybrid trials. The company also offers AI-assisted patient matching through an active patient registry, alongside biospecimen sourcing and logistics services. Infiuss has been backed by Y Combinator and 43North, and in 2022 received investment from UM6P Ventures aimed at expanding clinical trial access and health equity work in Africa.

Mendel.ai

Mendel.ai built its clinical trial matching capability around what it calls a Neuro-Symbolic AI system, which couples large language models with a proprietary hypergraph reasoning engine to sort patient cohorts from structured and unstructured electronic medical records. In a 2024 benchmark study conducted with Cornell University, the company reported its system outperformed GPT-4 at automatically retrieving eligible patient cohorts from a dataset of 1,400 patient records. Founded in 2017 by Dr. Karim Galil and CSO Wael Salloum and based in San Jose, California, Mendel's platform also supports chart review, prior authorization, and pharmacovigilance use cases beyond recruitment. The company's technology was originally built to help oncology patients find relevant trials faster than manual physician review allows.

Trial Library

Trial Library is a public benefit company built specifically around oncology clinical trial matching, embedding its AI-native platform directly into community oncology practices to identify eligible patients without adding outreach burden on providers. Founded by physician-scientist Dr. Hala Borno and based in San Francisco, the company partnered with American Oncology Network in 2025 to expand trial identification across practices in Missouri, Ohio, and North Carolina. Trial Library's stated mission centers on health equity in cancer care, aiming to make clinical trial access a standard part of care rather than an exception, particularly in communities that have historically been underserved. The company has raised a $10 million Series A round and also maintains partnerships with pharmaceutical sponsors including Johnson & Johnson Innovative Medicine.

TrialWire

TrialWire runs its AI and algorithm-driven recruitment platform on Salesforce Health Cloud, offering a pay-per-enrollment pricing model built around two named products: RapidStart for new study launches and RapidRescue for studies that have stalled. Based in San Francisco with additional offices in Sydney, Singapore, and Paris, the company reports its automated recruitment engine can activate within 24 hours of a sponsor request. TrialWire added an AI Voice Screen tool in 2025 aimed at capturing patients who might otherwise be missed due to language or health literacy barriers during phone-based screening. The company was named a finalist in Fierce Biotech's 2025 Fierce CRO Awards in the patient recruitment and retention category.

Tulip Trials

Tulip Trials describes its mission as accelerating clinical trials with AI, beginning with patient recruitment. The company is among a wave of AI-focused clinical trial technology startups that emerged in the early-to-mid 2020s, competing in a space that also includes larger, established platform providers, according to third-party competitive tracking. Detailed public information about Tulip Trials' specific platform capabilities, leadership, and headquarters location is limited beyond its own brief self-description. Sponsors evaluating the company are advised to confirm current capabilities directly.

Explore the full Patient Recruitment landscape

The companies above represent a portion of a much larger field.

Diligent's platform includes over 730 Patient Recruitment Vendors, with Vendor qualification data available on demand. Book a demo to explore Diligent's full vendor discovery database.

This article is intended as an informational overview of vendors operating in this space. Inclusion on this list does not constitute an endorsement, recommendation, or qualification by Diligent.